Canada’s reputation for pioneering gene and cell therapies remains strong, yet many patients continue to wait months or even years before those scientific breakthroughs become available at the bedside.
Approval does not guarantee access
Charmain Brown recalled the excitement that swept her family when a gene therapy designed for her children’s rare vision-loss condition received Health Canada authorization. The treatment demonstrated clear clinical benefit in trials, but the official approval did not translate into immediate availability for the patients who needed it.
Brown’s family soon faced a maze of questions: which hospitals possessed the necessary expertise to administer the treatment, how the drug would be sourced from the manufacturer, and whether provincial health plans would cover the steep cost. The resulting delay left them in limbo despite the therapy’s authorized status, forcing them to handle a complex web of logistical and financial hurdles.
Regulatory framework mismatched with living therapies
Modern regenerative medicines differ fundamentally from traditional pills because the manufacturing process often forms an integral part of the therapy itself. Some interventions are produced for a single patient, which makes the usual large-scale trial designs impossible to implement.
Current health-technology assessment models were built for 20th-century drugs and struggle to evaluate these “living” interventions. Consequently, patients with rare diseases may never see a treatment before the condition progresses beyond the point where it can be helped.
Calls for system modernization
This summer, the federal Pharmaceutical and Life Sciences Sector Task Force released a set of recommendations aimed at updating the review process for advanced therapies. The proposals call for more flexible regulatory pathways and coordinated support for innovators who are developing these cutting-edge products.
Faster coordination could shrink the interval between discovery and clinical use, allowing patients to benefit sooner.
Report highlights systemic gaps
A recent Stem Cell Network workshop gathered nearly 50 leaders from health-care and life-science sectors to examine three Canadian-origin innovations: a gene therapy for a fatal newborn disease, a tissue-engineered skin graft for severe burns, and a personalized treatment for a rare pediatric neurodevelopmental disorder.
Each case exposed a different weakness, ranging from regulatory bottlenecks to fragmented funding mechanisms. The findings stress the need for a system that adapts to therapy type, intended purpose, and population size, rather than forcing every product through a one-size-fits-all process.
Cate Murray, President and CEO of the Stem Cell Network, emphasized that hospitals must ready staff, facilities, diagnostics, and follow-up care while regulators, assessment bodies, and payers work in parallel. She added that funding models should cover the full cost chain, including patient travel and ancillary services.
One practical step would be to activate the existing Advanced Therapeutic Products framework across provinces, creating coordinated pathways from development through long-term evidence collection. Early navigation and clear prioritization could keep promising Canadian innovations from stalling at bureaucratic checkpoints.
Strategic implications for Canada
International competition for life-science talent and investment is intensifying as other nations roll out more adaptive policies. If Canada’s approval and reimbursement processes remain fragmented, researchers may take their breakthroughs to jurisdictions where the system is more responsive.
Health sovereignty, according to the report, involves not only manufacturing drugs domestically but also ensuring the entire pipeline—from discovery to patient delivery—functions smoothly. Canada already possesses world-class research and clinical expertise; the missing piece is integration of those strengths into a cohesive delivery network.
For families like Charmain Brown’s, the distinction between a scientific milestone and a usable treatment is stark. A therapy that sits behind regulatory or funding hurdles effectively remains out of reach, highlighting the urgency of system reform.
